ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Parse Launches GigaLab to Scale Single Cell Sequencing to Billions of Cells Annually

Demonstrates capabilities with 10 million cells and 1,000+ samples in a single run

Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced the launch of the Parse GigaLab™ to scale single cell sequencing to billions of cells per year. The GigaLab leverages Parse’s Evercode™ single cell technology with a scaled up workflow and expanded automation to enable discoveries never before deemed possible with current single cell approaches.

The GigaLab was built specifically for researchers scaling to projects of 10 million cells and much larger. The current capacity enables profiling of 2.5 billion cells per year and will continue to rapidly grow over time. Several early projects running at the GigaLab are already set to exceed the total number of cells available in all public single cell datasets to date. These new capabilities will be particularly enabling for researchers focused on large-scale drug and perturbation screens, dataset generation for generative AI models, and atlasing for population studies.

As an initial demonstration in partnership with Ultima Genomics, the developer of a revolutionary new ultra-high throughput next-generation sequencing (NGS) platform, Parse ran the first 10 million cell experiment with 1,092 samples in a single run, with all barcoding and library preparation taking just 3 days. This first of its kind study measured 90 cytokine perturbations across 18 immune cell types in 12 PBMC donors, resulting in over 19,000 observed perturbations. In addition to their partnership with Ultima, the Parse team collaborated with Professor Fabian Theis from Helmholtz Munich, whose lab developed the single cell computational biology tool, Scanpy. Theis and his lab are analyzing this 10 million cell dataset and leveraging it to train new AI models.

“Large-scale single cell perturbation datasets are exactly what the field needs to build and train models to help us better predict outcomes in both health and disease,” said Dr. Theis. He adds, “The speed and scale by which Parse is able to deliver these datasets is truly amazing and will accelerate the pace of discovery.”

“With Parse’s existing kits, researchers are now routinely profiling 1 million cells or nuclei in a single experiment,” states Charlie Roco, PhD, chief technology officer and co-founder of Parse Biosciences. He adds, “We still haven’t found a limit to the Evercode technology, and now with the GigaLab, we will usher in a new era of single cell analysis and redefine what’s possible to improve biological discovery and human health.”

Parse team members will be unveiling additional details about the GigaLab capabilities at the upcoming American Society of Human Genetics (ASHG) conference in a CoLab Theater talk (Theater 1) on November 6 at 2:30 PM local time and throughout the remainder of the conference in booth #703.

About Parse Biosciences

Parse Biosciences is a global life sciences company whose mission is to accelerate progress in human health and scientific research. Empowering researchers to perform single cell sequencing with unprecedented scale and ease, its pioneering approach has enabled groundbreaking discoveries in cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system.

With technology developed at the University of Washington by co-founders Alex Rosenberg and Charles Roco, Parse has raised over $100 million in capital and is now used by over 2,000 customers across the world. Its growing portfolio of products includes Evercode™ Whole Transcriptome, Evercode™ TCR, Evercode™ BCR, Gene Select, and a solution for data analysis, Trailmaker™.

Parse Biosciences is based in Seattle’s vibrant South Lake Union district, where it recently expanded into a new headquarters and state-of-the-art laboratory. To learn more, please visit https://www.parsebiosciences.com/.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.